Printer Friendly

THE IMMUNE RESPONSE CORPORATION PCR ASSAY CORRELATES VIRAL BURDEN WITH CLINICAL STAGE OF HIV INFECTION

 THE IMMUNE RESPONSE CORPORATION PCR ASSAY CORRELATES VIRAL BURDEN
 WITH CLINICAL STAGE OF HIV INFECTION
 SAN DIEGO, March 5 /PRNewswire/ -- The Immune Response Corporation (NASDAQ-NMS: IMNR) announced today that it has shown a correlation between HIV viral burden and the clinical stage of HIV infection using a quantitative PCR assay developed by the company. Patients in more advanced stages of disease, using the Walter Reed staging system, had significantly higher levels of virus in their blood, on average, than patients in the early, asymptomatic stages of disease. These results confirm the findings of other researchers that demonstrate that increased levels of HIV correlate with advanced patient status in this disease. The company believes this correlation supports the use of viral burden as one of several surrogate markers in the current Phase II/III clinical trial with the company's HIV therapeutic vaccine. None of the patients discussed in today's report has been treated with the company's HIV therapeutic vaccine, and the results presented here provide no indication of the efficacy or safety of this product.
 The results of this research are published in the current issue of AIDS Research and Human Retroviruses.
 This paper describes a quantitative polymerase chain reaction (PCR) assay developed by Immune Response to evaluate the amount of HIV DNA in the cells of HIV-infected patients. The reported data indicates that the PCR assay developed by Immune Response is sensitive and reproducible. With this assay, the company can quantitatively measure the level of HIV in a patient's blood. Data from this new PCR assay also correlate with the standard virus isolation assay.
 HIV viral burden, as measured by PCR and more traditional tests, is one of the surrogate markers that will be used to evaluate efficacy of the company's HIV therapeutic vaccine in an ongoing Phase II/III trial sponsored by The Immune Response Corporation and Rhone-Poulenc Rorer Inc. (NYSE: RPR). This trial is designed to evaluate the efficacy of the HIV therapeutic vaccine based upon multiple markers for disease progression in these patients. The company believes that the data presented in today's report support the significance of viral burden as a marker for disease progression and demonstrate the consistent quantitative evaluation possible with the company's PCR assay.
 The Immune Response Corporation is a biopharmaceutical company engaged in the development of proprietary products for the treatment of HIV infection, which leads to AIDS, and for the treatment of certain autoimmune diseases, particularly rheumatoid arthritis, multiple sclerosis and insulin-dependent diabetes.
 -0- 3/5/92
 /CONTACT: Steven Basta of The Immune Response Corporation, 619-431-7080/
 (IMNR RPR) CO: The Immune Response Corporation; Rhone-Poulenc Rorer Inc. ST: California IN: MTC SU:


DM-JL -- SD001 -- 5243 03/05/92 08:02 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 5, 1992
Words:448
Previous Article:SEMCOG TO HOLD GENERAL ASSEMBLY MEETING THURSDAY, MARCH 26
Next Article:CHEMICAL INDUSTRY COUNCIL OF NEW JERSEY RELEASES EMISSIONS REDUCTIONS REPORT
Topics:


Related Articles
CEL-SCI CORPORATION ANNOUNCES CLEARANCE FOR AIDS TRIAL
CLINICAL TRIALS BEGIN IN THAILAND OF HIV TREATMENT PROPOSED BY DR. JONAS SALK
CEL-SCI ANNOUNCES PRESENTATION OF CLINICAL DETAILS OF AIDS STUDY WITH HGP-30 VACCINE AT XI INTERNATIONAL CONFERENCE ON AIDS
The Immune Response Corporation Announces Publication of REMUNE(TM) Clinical Trial Data
Study of the Immune Response Corporation's Remune in Children Suggests Sustained Reduction of Viral Load.
The Immune Response Corporation Presents Data Suggesting That Remune May Have an Effect on the Control of HIV Infection.
The Immune Response Corporation Announces the Start of a Trial To Examine the Effects of REMUNE During Early-Stage HIV-Infection.
HIV Therapy With Remune(TM) Appears to Reconstitute Helper T-Cell Responses Against the Virus in Patients on Antiviral Drug Therapy.
Interim Results in a Patient Subset Indicate That Treatment With REMUNE(TM) and Antiviral Drugs May Stimulate 'Killer' T Cell Activity.
The Immune Response Corporation Announces the Addition of REMUNE(TM), An Investigational Therapeutic Vaccine for the Treatment of Primary HIV...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters